Breaking News Instant updates and real-time market news.

MRUS

Merus

$28.50

-1.48 (-4.94%)

, INCY

Incyte

$148.52

0.56 (0.38%)

05:36
03/21/17
03/21
05:36
03/21/17
05:36

Merus downgraded to Neutral from Buy at Citi

Citi analyst Yigal Nochomovitz downgraded Merus (MRUS) to Neutral saying that while the company's fundamentals continue to look "solid," the stock is fairy valued after rallying 50% following the Incyte (INCY) deal. The analyst raised his price target for the shares to $31 from $26.

MRUS

Merus

$28.50

-1.48 (-4.94%)

INCY

Incyte

$148.52

0.56 (0.38%)

  • 01

    Apr

  • 02

    Apr

  • 19

    Apr

MRUS Merus
$28.50

-1.48 (-4.94%)

12/21/16
JEFF
12/21/16
NO CHANGE
Target $29
JEFF
Buy
Jefferies ups Merus target to $29 after Incyte collaboration
Jefferies analyst Brian Abrahams views today's announced bispecific collaboration between Merus (MRUS) and Incyte (INCY) as a win for Merus. The deal provides "capital flexibility and strong validation" of the company's platform, while enabling maintenance of full rights to its clinical programs, Abrahams tells investors in a research note. He raised his price target for Merus shares to $29 from $21 and keeps a Buy rating on the name. The stock is up 45%, or $6.30, to $20.45 in midday trading.
12/22/16
SBSH
12/22/16
UPGRADE
Target $26
SBSH
Buy
Merus upgraded to Buy from Neutral at Citi
Citi analyst Yigal Nochomovitz upgraded Merus (MRUS) to Buy saying the Incyte (INCY) collaboration deal has "very favorable" terms. The deal with a "high-profile" company coupled with a $200M upfront payment "should meaningfully increase Street visibility," Nochomovitz tells investors in a research note. He raised his price target for Merus shares to $26 from $19. The stock closed yesterday up 43% to $20.22.
12/22/16
12/22/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Micron (MU) was upgraded to Buy from Hold at Cross Research, to Buy from Underperform at Needham, and to Buy from Hold at Summit Redstone. 2. Sunoco (SUN) upgraded to Outperform from Market Perform at FBR Capital with analyst Robert Balsamo saying the credit facility amendments announced reduce the need for a distribution cut. The analyst has a $32 price target for the shares. 3. National Instruments (NATI) upgraded to Outperform from Neutral at Baird with analyst Richard Eastman saying he sees the potential for accelerating revenue growth over the next few years combined with more determined focus to deliver operating leverage. 4. Merus (MRUS) upgraded to Buy from Neutral at Citi with analyst Yigal Nochomovitz saying the Incyte (INCY) collaboration deal has "very favorable" terms. 5. Sucampo (SCMP) upgraded to Buy from Neutral at Mizuho with the firm citing the sell-off in shares post the $260M convertible raise. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
12/28/16
JEFF
12/28/16
NO CHANGE
Target $29
JEFF
Buy
Merus still undervalued despite yesterday's rally, says Jefferies
Jefferies analyst Brian Abrahams says he continues to believe shares of Merus (MRUS) are undervalued. The stock rose 5% yesterday to $20.91. Seattle Genetics' (SGEN) toxicity roadblock highlights the unmet need for new mechanisms, but also the challenges in acute myeloid leukemia, Abrahams tells investors in a research note. Merus' MCLA-117 has looked safe thus far and has a differentiated profile, the analyst contends. He keeps a Buy rating on the shares with a $29 price target.
INCY Incyte
$148.52

0.56 (0.38%)

01/31/17
RHCO
01/31/17
NO CHANGE
RHCO
Incyte price target raised to $140 from $115 at SunTrust
SunTrust analyst Peter Lawson raised his price target on Incyte (INCY), citing "increased pipeline & technology value" as data releases and PDUFA dates approach. Additionally, the analyst is upbeat on the company's global collaboration deal with Calithera (CALA), saying that the deal expands Incyte's "reach into the (immuno-oncology) space." The analyst reiterates a Buy rating on Incyte.
03/01/17
NOMU
03/01/17
INITIATION
Target $148
NOMU
Buy
Incyte initiated with a Buy at Nomura
Nomura initiated Incyte with a Buy and a $148 price target.
03/08/17
UBSW
03/08/17
INITIATION
Target $140
UBSW
Neutral
Incyte initiated with a Neutral at UBS
UBS analyst Carter Gould initiated Incyte with a Neutral and a $140 price target.
03/13/17
FBCO
03/13/17
NO CHANGE
Target $174
FBCO
Outperform
Incyte price target raised to $174 from $136 at Credit Suisse
Credit Suisse analyst Kennen MacKay raised his price target for Incyte (INCY) to $174 upon shifting to an M&A discounted cash flow net present value methodology. Incyte rallied late in the day on Friday amid speculation of a takeover by Gilead Sciences (GILD). Incyte could provide an attractive entry into immuno-oncology for an acquirer, MacKay tells investors in a research note. The company's epacadostat could be a "scarce immuno-oncology backbone blockbuster," the analyst contends. He anticipates "significant interest" in Incyte for this reason. MacKay keeps an Outperform rating on the shares.

TODAY'S FREE FLY STORIES

FDS

FactSet

$185.76

3.5 (1.92%)

07:39
10/23/17
10/23
07:39
10/23/17
07:39
Recommendations
FactSet analyst commentary  »

FactSet price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EVOK

Evoke Pharma

$3.44

0.07 (2.08%)

07:39
10/23/17
10/23
07:39
10/23/17
07:39
Hot Stocks
Evoke Pharma announces topline results from comparative exposure PK study »

Evoke Pharma announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

07:38
10/23/17
10/23
07:38
10/23/17
07:38
Conference/Events
JPMorgan to hold a forum »

Japan FinTech Forum is…

07:38
10/23/17
10/23
07:38
10/23/17
07:38
Conference/Events
Piper Jaffray to hold a field trip »

Brazilian Agricultural…

EFX

Equifax

$109.97

-0.54 (-0.49%)

07:38
10/23/17
10/23
07:38
10/23/17
07:38
Downgrade
Equifax rating change  »

Equifax downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Oct

  • 14

    Dec

CX

Cemex

$7.96

-0.13 (-1.61%)

07:37
10/23/17
10/23
07:37
10/23/17
07:37
Upgrade
Cemex rating change  »

Cemex upgraded to Neutral…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ABT

Abbott

$56.32

0.32 (0.57%)

, MD

Mednax

07:36
10/23/17
10/23
07:36
10/23/17
07:36
Conference/Events
American Society of Anesthesiology to hold annual meeting »

Anesthesiology 2017…

ABT

Abbott

$56.32

0.32 (0.57%)

MD

Mednax

ABBV

AbbVie

$96.10

-0.38 (-0.39%)

BAX

Baxter

$63.59

0.12 (0.19%)

CAE

CAE

$17.43

0.01 (0.06%)

DDD

3D Systems

$12.00

0.53 (4.62%)

EM

Emdeon

XENE

Xenon Pharmaceuticals

$3.25

0.05 (1.56%)

TRVN

Trevena

$1.76

0.1 (6.02%)

SIEGY

Siemens

$68.33

-1.245 (-1.79%)

NOVA

NovaMed

NUVA

NuVasive

$55.05

0.48 (0.88%)

PFE

Pfizer

$36.42

0.18 (0.50%)

INFI

Infinity Pharmaceuticals

$2.28

-0.12 (-5.00%)

KRO

Kronos Worldwide

$26.17

0.35 (1.36%)

MNK

Mallinckrodt

$32.42

-0.4 (-1.22%)

HAE

Haemonetics

$45.66

0.55 (1.22%)

EW

Edwards Lifesciences

$113.08

1.05 (0.94%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 25

    Oct

  • 25

    Oct

  • 27

    Oct

  • 31

    Oct

  • 31

    Oct

  • 01

    Nov

  • 06

    Nov

  • 07

    Nov

  • 07

    Nov

  • 07

    Nov

  • 08

    Nov

  • 07

    Dec

CMCSA

Comcast

$37.22

0.32 (0.87%)

07:35
10/23/17
10/23
07:35
10/23/17
07:35
Recommendations
Comcast analyst commentary  »

Comcast video losses do…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Oct

  • 01

    Nov

ENTA

Enanta

$48.16

0.76 (1.60%)

07:35
10/23/17
10/23
07:35
10/23/17
07:35
Hot Stocks
Enanta announces 'positive' Phase 1 a/b clinical results for EDP-305 »

Enanta Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

KMB

Kimberly-Clark

$113.44

-2.11 (-1.83%)

07:35
10/23/17
10/23
07:35
10/23/17
07:35
Hot Stocks
Breaking Hot Stocks news story on Kimberly-Clark »

Kimberly-Clark sees FY17…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

VZ

Verizon

$49.53

0.32 (0.65%)

, UNP

Union Pacific

$112.99

0.98 (0.87%)

07:35
10/23/17
10/23
07:35
10/23/17
07:35
Options
Unusual call flow in option market yesterday »

Notable call activity was…

VZ

Verizon

$49.53

0.32 (0.65%)

UNP

Union Pacific

$112.99

0.98 (0.87%)

S

Sprint

$6.93

-0.14 (-1.98%)

PYPL

PayPal

$70.97

3.72 (5.53%)

CTL

CenturyLink

$19.04

0.55 (2.97%)

NSC

Norfolk Southern

$132.75

2.51 (1.93%)

FEYE

FireEye

$16.81

-0.01 (-0.06%)

AMTD

TD Ameritrade

$48.27

0.88 (1.86%)

PRU

Prudential

$110.78

1.18 (1.08%)

AVP

Avon Products

$2.28

0.02 (0.88%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 25

    Oct

  • 26

    Oct

  • 27

    Oct

  • 01

    Nov

  • 01

    Nov

  • 02

    Nov

  • 02

    Nov

  • 07

    Nov

  • 07

    Nov

  • 15

    Nov

  • 29

    Nov

  • 07

    Dec

  • 16

    May

MRK

Merck

$63.88

0.13 (0.20%)

, TKPYY

Takeda Pharmaceutical Co. Ltd.

$28.07

-0.15 (-0.53%)

07:34
10/23/17
10/23
07:34
10/23/17
07:34
Conference/Events
World Congress to hold a summit »

5th Annual Patient…

MRK

Merck

$63.88

0.13 (0.20%)

TKPYY

Takeda Pharmaceutical Co. Ltd.

$28.07

-0.15 (-0.53%)

PFE

Pfizer

$36.42

0.18 (0.50%)

AGN

Allergan

$188.28

-0.99 (-0.52%)

ONCE

Spark Therapeutics

$81.87

1.08 (1.34%)

PODD

Insulet

$61.58

-0.39 (-0.63%)

ACHN

Achillion

$4.15

-0.01 (-0.24%)

SNY

Sanofi

$49.51

-0.51 (-1.02%)

ABEO

Abeona Therapeutics

$19.00

1.25 (7.04%)

JNJ

Johnson & Johnson

$142.40

0.36 (0.25%)

AZN

AstraZeneca

$34.62

-0.09 (-0.26%)

SHPG

Shire

$145.25

-2.57 (-1.74%)

GSK

GlaxoSmithKline

$40.84

-0.26 (-0.63%)

BMY

Bristol-Myers

$64.42

-0.25 (-0.39%)

SCMP

Sucampo

$10.30

0.05 (0.49%)

PCRX

Pacira

$33.50

0.4 (1.21%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 24

    Oct

  • 25

    Oct

  • 25

    Oct

  • 25

    Oct

  • 26

    Oct

  • 27

    Oct

  • 27

    Oct

  • 31

    Oct

  • 01

    Nov

  • 02

    Nov

  • 06

    Nov

  • 07

    Nov

  • 08

    Nov

  • 09

    Nov

  • 09

    Nov

  • 16

    Nov

  • 30

    Nov

  • 12

    Jan

  • 02

    Feb

  • 05

    Mar

  • 06

    Apr

AAPL

Apple

$156.25

0.27 (0.17%)

07:34
10/23/17
10/23
07:34
10/23/17
07:34
Recommendations
Apple analyst commentary  »

Apple supply/demand…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Nov

TMUS

T-Mobile

$60.46

-1.05 (-1.71%)

07:33
10/23/17
10/23
07:33
10/23/17
07:33
Hot Stocks
T-Mobile raises low end of postpaid net custuomer adds view to 3.3M-3.6M »

T-Mobile says, "We…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

  • 01

    Nov

KMB

Kimberly-Clark

$113.44

-2.11 (-1.83%)

07:33
10/23/17
10/23
07:33
10/23/17
07:33
Hot Stocks
Kimberly-Clark says Q3 a 'challenging environment' »

Chairman and CEO Thomas…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

07:33
10/23/17
10/23
07:33
10/23/17
07:33
Conference/Events
The U.S. Commodity Futures Trading Commission holds a symposium »

25th Annual Symposium is…

BKS

Barnes & Noble

$7.35

0.15 (2.08%)

07:33
10/23/17
10/23
07:33
10/23/17
07:33
Conference/Events
Barnes & Noble management to meet with Sidoti »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

TMUS

T-Mobile

$60.46

-1.05 (-1.71%)

07:32
10/23/17
10/23
07:32
10/23/17
07:32
Hot Stocks
T-Mobile sees FY branded postpaid phone ARPU 'generally stable' to FY16 »

T-Mobile continues to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

  • 01

    Nov

DCPH

Deciphera

$20.15

0.31 (1.56%)

07:32
10/23/17
10/23
07:32
10/23/17
07:32
Initiation
Deciphera initiated  »

Deciphera initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KMB

Kimberly-Clark

$113.44

-2.11 (-1.83%)

07:32
10/23/17
10/23
07:32
10/23/17
07:32
Earnings
Kimberly-Clark backs FY17 EPS view at low end of $6.20-$6.35 »

FY17 consensus $6.20. The…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

ZKIN

ZK International Group

$8.23

0.07 (0.86%)

07:32
10/23/17
10/23
07:32
10/23/17
07:32
Hot Stocks
ZK International Group invited by Shenzhen Water Group »

ZK International Group…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TMUS

T-Mobile

$60.46

-1.05 (-1.71%)

07:31
10/23/17
10/23
07:31
10/23/17
07:31
Earnings
T-Mobile reports Q3 EPS 63c, consensus 46c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

  • 01

    Nov

EGL

Engility

$33.41

-0.11 (-0.33%)

07:31
10/23/17
10/23
07:31
10/23/17
07:31
Hot Stocks
Engility wins $14M contract from Defense Intelligence Agency »

Engility Holdings won a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Nov

  • 09

    Nov

  • 14

    Dec

ROKU

Roku

$21.87

-0.16 (-0.73%)

07:31
10/23/17
10/23
07:31
10/23/17
07:31
Initiation
Roku initiated  »

Roku initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Nov

DHI

D.R. Horton

$42.67

0.14 (0.33%)

07:30
10/23/17
10/23
07:30
10/23/17
07:30
Recommendations
D.R. Horton analyst commentary  »

D.R. Horton price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Nov

  • 14

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.